metabolic syndrome

bmi kg

prevalence obesity

sarcopenic obesity

physical activity

sarcopenia

mass index bmi

Obesity Reviews

Summary Aging and obesity are two global concerns in public health. Sarcopenic obesity (SO), defined as the combination of age‐related sarcopenia and obesity, has become a pressing issue. This systematic review and meta‐analysis summarize the current clinical evidence relevant to SO. PubMed, Embase, and Web of Science were searched, and 106 clinical studies with 167,151 elderlies were included. The estimated prevalence of SO was 9% in both men and women. Obesity was associated with 34% reduced risk of sarcopenia (odds ratio [OR] 0.66, 95% CI 0.48–0.91; p &lt; 0.001). The pooled hazard ratio (HR) of all‐cause mortality was 1.51 (95% CI 1.14–2.02; p &lt; 0.001) for people with SO compared with healthy individuals. SO was associated with increased risk of cardiovascular disease and related mortality, metabolic disorders, cognitive impairment, arthritis, functional limitation, and lung diseases (all ORs &gt; 1.0, p &lt; 0.05). The attenuated risk of sarcopenia in elderlies with obesity (“obesity paradox”) was dependent on higher muscle mass and strength. Apart from unifying the diagnosis of SO, more research is needed to subphenotype people with obesity and sarcopenia for individualized treatment. Meanwhile, the maintenance of proper body composition of muscle and fat may delay or attenuate the adverse outcomes of aging.

Deciphering the “obesity paradox” in the elderly: A systematic review and meta‐analysis of sarcopenic obesity